دورية أكاديمية
أعرض في EDS

Histopathology of telomerase reverse transcriptase promoter ( TERT ) mutated indeterminate thyroid nodules.

التفاصيل البيبلوغرافية
العنوان: Histopathology of telomerase reverse transcriptase promoter ( TERT ) mutated indeterminate thyroid nodules.
المؤلفون: Pinto JO; Department of Internal Medicine, University of Washington, Seattle, WA, USA., Livhits MJ; Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Yeh MW; Section of Endocrine Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA, USA., Kaykov A; Department of Marketing, Veracyte, South San Francisco, CA, USA., Klopper JP; Department of Medical Affairs, Veracyte, Inc., South San Francisco, CA. USA., Kloos RT; Department of Medical Affairs, Veracyte, Inc., South San Francisco, CA. USA., Alshalalfa M; Department of Research and Development, Veracyte, South San Francisco, CA, USA., Hao Y; Department of Research and Development, Veracyte, South San Francisco, CA, USA., Huang J; Department of Research and Development, Veracyte, South San Francisco, CA, USA., Endo M; Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, WA, USA.
المصدر: Journal of clinical & translational endocrinology [J Clin Transl Endocrinol] 2023 Dec 02; Vol. 35, pp. 100329. Date of Electronic Publication: 2023 Dec 02 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: Netherlands NLM ID: 101629335 Publication Model: eCollection Cited Medium: Internet ISSN: 2214-6237 (Electronic) Linking ISSN: 22146237 NLM ISO Abbreviation: J Clin Transl Endocrinol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier Inc.
مستخلص: Objective: The objective of this study was to analyze the risk of malignancy and the histopathology of telomerase reverse transcriptase promoter (TERT) mutated cytologically indeterminate thyroid nodules (ITN).
Methods: A PUBMED search of molecularly tested ITN was conducted and data on TERT mutated ITN with histopathology correlation were extracted.
Results: Twenty-six manuscripts (published between 2014 and 2022) reported on 77 TERT mutated ITN. Sixty-five nodules were malignant (84 %), with 16 (25 %) described with high-risk histopathology, 5 (8 %) described as low-risk, and most without any description. Isolated TERT mutations were malignant in 26/30 ITNs (87 %) with 9 (35 %) described as high risk and none described as low risk. TERT  +  RAS mutated ITNs were malignant in 29/34 ITNs (85 %) with 3 (10 %) described as high risk and 4 (14 %) described as low risk. Finally, all 5 TERT  +  BRAF V600E mutated nodules were malignant and 3/5 (60 %) were described as high risk.
Conclusion: TERT mutated ITNs have a high risk of malignancy (84 %), and the current data does not show a difference in malignancy rate between isolated TERT mutations and TERT  +  RAS co-mutated ITNs. When described, TERT  +  RAS co-mutated ITNs did not have a higher rate of high-risk histopathology as compared to isolated TERT mutated lesions. Most TERT mutated ITNs did not have a description of histopathology risk and the oncologic outcomes, including rate of recurrence, metastases, and disease specific survival, are unknown. Further data is needed to determine if TERT mutated ITNs should be subjected to aggressive initial treatment.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Atanas Kaykov, Joshua P. Klopper, Richard T. Kloos, Mohammed Alshalalfa, Yangyang Hao, and Jing Huang are employees and equity owners of Veracyte, Inc.
(© 2023 Published by Elsevier Inc.)
References: J Clin Invest. 2016 Mar 1;126(3):1052-66. (PMID: 26878173)
Endocr Relat Cancer. 2014 Oct;21(5):825-30. (PMID: 25121551)
Thyroid. 2022 Nov;32(11):1372-1381. (PMID: 35950639)
J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6. (PMID: 23833040)
Clin Endocrinol (Oxf). 2021 May;94(5):731-742. (PMID: 32816325)
Nat Commun. 2013;4:2185. (PMID: 23887589)
Thyroid. 2016 Jan;26(1):1-133. (PMID: 26462967)
Oncogene. 2014 Oct 16;33(42):4978-84. (PMID: 24141777)
Cancers (Basel). 2023 Jan 08;15(2):. (PMID: 36672362)
Genome Med. 2016 Jun 20;8(1):69. (PMID: 27323951)
J Clin Endocrinol Metab. 2023 Oct 18;108(11):2999-3008. (PMID: 37071871)
Cell. 2014 Oct 23;159(3):676-90. (PMID: 25417114)
Front Endocrinol (Lausanne). 2023 Feb 24;14:1101410. (PMID: 36909304)
Diagn Pathol. 2016 Feb 09;11:21. (PMID: 26857243)
Endocr Relat Cancer. 2016 Mar;23(3):R143-55. (PMID: 26733501)
Cancers (Basel). 2021 Feb 05;13(4):. (PMID: 33562809)
Rev Esp Cardiol (Engl Ed). 2021 Sep;74(9):790-799. (PMID: 34446261)
Cancer. 2016 May 1;122(9):1370-9. (PMID: 26969876)
Clin Transl Med. 2022 Nov;12(11):e1111. (PMID: 36394204)
Thyroid. 2017 May;27(5):651-660. (PMID: 28181854)
Thyroid. 2019 Nov;29(11):1594-1605. (PMID: 31469053)
فهرسة مساهمة: Keywords: Indeterminate cytology; Molecular markers; Systematic review; TERT; Thyroid cancer; Thyroid nodule
تواريخ الأحداث: Date Created: 20231220 Latest Revision: 20231221
رمز التحديث: 20231221
مُعرف محوري في PubMed: PMC10727925
DOI: 10.1016/j.jcte.2023.100329
PMID: 38116167
قاعدة البيانات: MEDLINE
الوصف
تدمد:2214-6237
DOI:10.1016/j.jcte.2023.100329